Villere ST Denis J & Co. LLC Acquires 70,613 Shares of Pfizer Inc. $PFE

Villere ST Denis J & Co. LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 14.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 574,968 shares of the biopharmaceutical company’s stock after acquiring an additional 70,613 shares during the quarter. Villere ST Denis J & Co. LLC’s holdings in Pfizer were worth $16,145,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in PFE. Penn Davis Mcfarland Inc. lifted its position in Pfizer by 50.9% in the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after purchasing an additional 57,777 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after purchasing an additional 5,978,927 shares during the last quarter. Danske Bank A S purchased a new position in shares of Pfizer in the third quarter worth $81,298,000. Vanguard Group Inc. raised its holdings in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after buying an additional 7,031,162 shares during the last quarter. Finally, KBC Group NV raised its holdings in Pfizer by 8.3% during the 4th quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company’s stock valued at $228,924,000 after buying an additional 706,426 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.1%

Pfizer stock traded down $0.04 on Friday, hitting $24.21. 27,476,453 shares of the stock traded hands, compared to its average volume of 47,734,172. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75. The firm has a market cap of $138.01 billion, a P/E ratio of 18.48 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The business’s fifty day simple moving average is $25.37 and its 200 day simple moving average is $26.18.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period last year, the company posted $0.92 EPS. Pfizer’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.97 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer, expanding the label for a key Pfizer/Astellas regimen and potentially opening the door to more sales in oncology. Article: U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
• Positive Sentiment: Pfizer’s oncology story also got incremental attention from a completed lorlatinib lung cancer study and other clinical updates, which keep investors focused on the company’s pipeline rather than only its mature products. Article: Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors
• Neutral Sentiment: Bank of America lowered its price target on Pfizer to $26 from $27 while keeping a neutral rating, signaling limited upside but no major change in its overall stance. Article: Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00.
• Negative Sentiment: Several market commentary pieces highlighted concerns about Pfizer’s growth outlook and mixed second-quarter expectations, including skepticism about how quickly Seagen-related benefits will show up in results. Article: Pfizer Poised for Mixed Second Quarter, RBC Says

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. UBS Group reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Guggenheim raised their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. dropped their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $28.56.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.